Third positive data review by IDSMB follows completion of patient recruitment.
Paris and Boston, July 11th, 2017 – Neovacs (Euronext Growth: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it received a positive data review by the Independent Data and Safety Monitoring Board (IDSMB) for the ongoing Phase IIb Clinical Trial of IFNα Kinoid in lupus.
This is the third IDSMB data review of the ongoing Phase IIb clinical trial. The board reviewed the cumulative data, notably safety data from the study and informed the company that it has identified no safety concerns, and recommended the continuation of the study without any modifications. The trial is now fully enrolled with 178 patients randomized to receive either injection IFNα Kinoid vaccine or placebo.